Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H21NO2 |
Molecular Weight | 271.3541 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCCC(OC1=C(OC)C=CC=C1)C2=CC=CC=C2
InChI
InChIKey=ITJNARMNRKSWTA-UHFFFAOYSA-N
InChI=1S/C17H21NO2/c1-18-13-12-15(14-8-4-3-5-9-14)20-17-11-7-6-10-16(17)19-2/h3-11,15,18H,12-13H2,1-2H3
Nisoxetine, 3-(o-methoxyphenoxy)-3-phenyl-N-methyl-propyl-amine, is a most active and selective inhibitor of norepinephrine uptake, which was developed by Eli Lilly as an antidepressant drug. It was shown that nisoxetine dose-dependently reduced acute food intake and the additive effect of it was preserved in obese mice. In addition, was revealed that nisoxetine produced local but not systemic analgesia against cutaneous nociceptive stimuli in rodents. However, this drug has no clinical applications in humans.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15219270
Curator's Comment: Known to be CNS penetrant in rat. Human data not available
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11082428 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/788744
Placebo and nisoxetine (10-20 mg b.d. for 7 days) were administered to normal volunteers in a single-bind crossover study. Adverse side effects were minimal. There were no significant changes in heart rate or blood pressure seen when no other drugs were given. The effect of nisoxetine on uptake of biogenic amines was utilized to study its mechanism of action.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8218295
It was investigated the interaction of nisoxetine with the human norepinephrine transporter by examining the binding of this ligand to the placental brush border membranes. Scatchard analysis revealed that nisoxetine bound with high affinity to a single class of binding sites in the membranes (dissociation constant = 13.8 +/- 0.4 nM). This value obtained from equilibrium experiments matched the value (11.2 nM) which was calculated using the association and dissociation rate constants. The maximal binding capacity (Bmax) was 5.1 +/- 0.1 pmol/mg of protein. The binding exhibited an absolute requirement for Na+ as well as Cl-. Presence of these ions enhanced the binding affinity without affecting Bmax. Kinetic analyses revealed that the coupling ratio of Na+/nisoxetine was 2, whereas the coupling ratio of Cl-/nisoxetine was 1.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 16:12:58 GMT 2023 , Edited by admin on Fri Dec 15 16:12:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
53179-07-0
Created by
admin on Fri Dec 15 16:12:57 GMT 2023 , Edited by admin on Fri Dec 15 16:12:57 GMT 2023
|
PRIMARY | |||
|
73410
Created by
admin on Fri Dec 15 16:12:57 GMT 2023 , Edited by admin on Fri Dec 15 16:12:57 GMT 2023
|
PRIMARY | |||
|
DTXSID0045175
Created by
admin on Fri Dec 15 16:12:57 GMT 2023 , Edited by admin on Fri Dec 15 16:12:57 GMT 2023
|
PRIMARY | |||
|
C75172
Created by
admin on Fri Dec 15 16:12:58 GMT 2023 , Edited by admin on Fri Dec 15 16:12:58 GMT 2023
|
PRIMARY | |||
|
3878
Created by
admin on Fri Dec 15 16:12:58 GMT 2023 , Edited by admin on Fri Dec 15 16:12:58 GMT 2023
|
PRIMARY | |||
|
DB09186
Created by
admin on Fri Dec 15 16:12:57 GMT 2023 , Edited by admin on Fri Dec 15 16:12:57 GMT 2023
|
PRIMARY | |||
|
C011386
Created by
admin on Fri Dec 15 16:12:58 GMT 2023 , Edited by admin on Fri Dec 15 16:12:58 GMT 2023
|
PRIMARY | |||
|
4500
Created by
admin on Fri Dec 15 16:12:58 GMT 2023 , Edited by admin on Fri Dec 15 16:12:58 GMT 2023
|
PRIMARY | |||
|
100000083909
Created by
admin on Fri Dec 15 16:12:58 GMT 2023 , Edited by admin on Fri Dec 15 16:12:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL295467
Created by
admin on Fri Dec 15 16:12:57 GMT 2023 , Edited by admin on Fri Dec 15 16:12:57 GMT 2023
|
PRIMARY | |||
|
SUB09308MIG
Created by
admin on Fri Dec 15 16:12:57 GMT 2023 , Edited by admin on Fri Dec 15 16:12:57 GMT 2023
|
PRIMARY | |||
|
NISOXETINE
Created by
admin on Fri Dec 15 16:12:58 GMT 2023 , Edited by admin on Fri Dec 15 16:12:58 GMT 2023
|
PRIMARY | |||
|
283481
Created by
admin on Fri Dec 15 16:12:58 GMT 2023 , Edited by admin on Fri Dec 15 16:12:58 GMT 2023
|
PRIMARY | |||
|
17NV064B2D
Created by
admin on Fri Dec 15 16:12:57 GMT 2023 , Edited by admin on Fri Dec 15 16:12:57 GMT 2023
|
PRIMARY |
ACTIVE MOIETY